drugset
drugset / Trial / NCT06118021

A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

NCT06118021 ↗

Phase 2 Completed 200 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a study of HS-20094 in participants with overweight and obesity. The main purpose is to learn more about how HS-20094 affects body weight. The study period including 4-12 weeks dose titration and 12-20 weeks maintain treatment and 6 weeks follow up.

Timeline

Start
2023-10-16
Primary completion
2024-08-13
Completion
2024-08-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Olatorepatide Protein / enzyme biologic 5 mg Subcutaneous
Subject Olatorepatide Protein / enzyme biologic 10 mg Subcutaneous
Subject Olatorepatide Protein / enzyme biologic 15 mg Subcutaneous
Subject Olatorepatide Protein / enzyme biologic 20 mg Subcutaneous

Indications

No indication recorded.